Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.

ABSTRACT: Prostate cancer is a leading cause of cancer-related deaths in men in the United States. Although treatable when detected early, prostate cancer commonly transitions to an aggressive castration-resistant metastatic state. While taxane chemotherapeutics such as docetaxel are mainstay treatment options for prostate cancer, taxane resistance often develops. Fatty acid binding protein 5 (FABP5) is an intracellular lipid chaperone that is upregulated in advanced prostate cancer and is implicated as a key driver of its progression. The recent demonstration that FABP5 inhibitors produce synergistic inhibition of tumor growth when combined with taxane chemotherapeutics highlights the possibility that FABP5 may regulate other features of taxane function, including resistance. Employing taxane-resis

SUBMITTER: Hillowe A 

PROVIDER: S-EPMC10553314 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature